- Rating
- 1
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
OT-PRS aligns SNPs across populations using fused Gromov-Wasserstein transport, transfers source effects into a prior, and refines them with target GWAS statistics. Transport entropy supplies additional weighting and prediction features. Evaluation covers nine UK Biobank disease-ancestry tasks and covariate-adjusted discrimination in All of Us.
Critical strengths
-
The transport objective and target-effect refinement provide an explicit, inspectable formulation of cross-population information transfer.
-
The target-only and identity-prior ablations directly examine the distinctive transport component, while the paper appropriately distinguishes entropy from calibrated predictive uncertainty.
Critical weaknesses
-
The primary evaluation does not establish discovery–evaluation independence. The UK Biobank analysis uses GWAS statistics and evaluation genotypes from the same resource, while cross-validation partitions only downstream phenotype-model fitting. Potential overlap is acknowledged, but exclusion of evaluation individuals from discovery is not established; consequently, the AUCs, pseudo-R² values, and rankings in Section 5.1 cannot establish independent genetic prediction.
-
The external study does not resolve the central validation gap. Figure 5 reports only the full covariate-adjusted model in All of Us, without covariate-only, competing PRS, or matched-prior results. As Section 5.2 acknowledges, this does not isolate the genetic increment; the fitting and evaluation separation for the external regression also needs clarification before these AUCs establish the proposed method's predictive advantage.
-
The matched ablation provides little evidence for the distinctive transport mechanism. Section 5.3.1 reports mean AUCs of 0.7691 for OT and 0.7690 for an identity prior under matched conditions. This does not show that cross-SNP redistribution adds meaningfully beyond target refinement and direct borrowing; the larger differences against feature-only or structure-only transport in Figure 6 do not resolve that question.
-
Signed effect transfer lacks a sufficiently justified correspondence. The transport cost uses allele-frequency differences and unsigned LD geometry, whereas Equation 2 averages signed effects across different variants. Harmonizing the same variant across populations does not determine the appropriate relative sign between distinct variants, so lower alignment cost need not preserve useful tagging effects; this weakens the biological motivation for the proposed prior.
-
The effect-size parameterization is insufficiently specified to assess the estimator. Equation 3 relates marginal effects to joint effects through the correlation matrix R, while Equation 5 scores effect-allele dosages. These expressions require compatible standardized or per-allele coefficient conventions and the corresponding genotype-variance conversion; without those definitions, it is unclear whether target refinement and downstream scoring estimate the same genetic quantity.
-
The transport-derived uncertainty measure lacks empirical validation. The method uses transport entropy to quantify alignment ambiguity and attenuate SNP effects, but does not establish that higher entropy corresponds to less reliable effect transfer or greater prediction error. Appendix D.4 shows that most SNPs have highly diffuse alignments (median entropy 0.924), resulting in substantial attenuation of effects. Although the authors acknowledge that entropy is not calibrated predictive uncertainty, its usefulness as a reliability measure is not demonstrated.
Questions for authors
-
Can the primary comparison and identity-prior ablation be evaluated with strictly disjoint GWAS discovery and test samples? In All of Us, what are the held-out genetic increments over covariates alone and the corresponding baseline PRS methods?
-
Are the external regression coefficients fitted and evaluated on separate individuals? What effect-size conventions connect Equations 3 and 5, including any genotype-standard-deviation conversions?
-
What justifies transferring effect signs across distinct SNPs under an unsigned alignment cost, and is the resulting score stable under consistent alternative effect-allele coding?